These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1557641)

  • 1. Modulation of fluorouracil toxicity with uridine.
    van Groeningen CJ; Peters GJ; Pinedo HM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):148-54. PubMed ID: 1557641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
    van Groeningen CJ; Peters GJ; Leyva A; Laurensse E; Pinedo HM
    J Natl Cancer Inst; 1989 Jan; 81(2):157-62. PubMed ID: 2909757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine.
    van Groeningen CJ; Peters GJ; Pinedo HM
    Ann Oncol; 1993 Apr; 4(4):317-20. PubMed ID: 8518223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
    van Groeningen CJ; Leyva A; Kraal I; Peters GJ; Pinedo HM
    Cancer Treat Rep; 1986 Jun; 70(6):745-50. PubMed ID: 3731137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
    Kelsen DP; Martin D; O'Neil J; Schwartz G; Saltz L; Sung MT; von Borstel R; Bertino J
    J Clin Oncol; 1997 Apr; 15(4):1511-7. PubMed ID: 9193347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
    Saif MW; Diasio RB
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
    Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
    Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil.
    Bagrij T; Kralovanszky J; Gyergyay F; Kiss E; Peters GJ
    Anticancer Res; 1993; 13(3):789-93. PubMed ID: 8317913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
    Martin DS; Stolfi RL; Sawyer RC
    Cancer Chemother Pharmacol; 1989; 24(1):9-14. PubMed ID: 2720896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
    Pizzorno G; Yee L; Burtness BA; Marsh JC; Darnowski JW; Chu MY; Chu SH; Chu E; Leffert JJ; Handschumacher RE; Calabresi P
    Clin Cancer Res; 1998 May; 4(5):1165-75. PubMed ID: 9607574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
    Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
    Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.
    Peters GJ; van Dijk J; Laurensse E; van Groeningen CJ; Lankelma J; Leyva A; Nadal JC; Pinedo HM
    Br J Cancer; 1988 Mar; 57(3):259-65. PubMed ID: 3355763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of 5-FU action by thymidine in murine and human tumors.
    Young CW; Woodcock TM; Martin DS
    Cancer Treat Rep; 1981; 65 Suppl 3():83-7. PubMed ID: 7346156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
    Grem JL; Chu E; Boarman D; Balis FM; Murphy RF; McAtee N; Allegra CJ
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):36-44. PubMed ID: 1557656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
    Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of potentiation of antitumor activity of 5-fluorouracil by ribothymidine in a mouse tumor system.
    Tezuka M; Chiba Y; Tamemasa O; Okada S
    J Pharmacobiodyn; 1986 Dec; 9(12):962-9. PubMed ID: 3572717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
    Saif MW; von Borstel R
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):136-42. PubMed ID: 16187114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.